Spondyloarthritis & psoriatic arthritis
Risk of infections in psoriatic arthritis or axial spondyloarthritis patients treated with targeted therapies: A meta-analysis of randomized controlled trials
Pooled result · Any infectionResult — go to the resultRelative risk 1.15 95% CI 1.06–1.25Authors' conclusion
In contrast to serious infections, the risk of global infections is moderately increased with b/tsDMARDs in spondyloarthritis, and is associated in particular with use of TNF and IL-17 inhibitors.
Study context
- Population
- Patients with PsA or axial SpA (ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)) in randomized controlled trials (RCTs) of b/tsDMARDs
- Participants
- 20,418 patients60 RCTs
- Comparison
- b/tsDMARDs vs placebo, csDMARDs or non-steroidal anti-inflammatory drugs (NSAIDs)
- Outcome
- Global infections (any infections reported, including bacterial, viral and fungal, except serious infections)
Pooled result
Any infection
Relative risk
1.15
95% CI 1.06–1.25
b/tsDMARDsvs Placebo, csDMARDs or NSAIDs
RR 1.15 (95% CI 1.06–1.25)
As reported in the abstract
Further pooled results
Any infection in axial spondyloarthritis patients (subgroup)
- RR, 95% CI 1.14-1.52 (statistically significant increased risk)
- 1.32
Any infection in PsA patients (subgroup)
- RR, 95% CI 0.97-1.14 (not significant)
- 1.05
Any infection with TNF inhibitors (subgroup)
- RR, 95% CI 1.11-1.37
- 1.23
Any infection with IL-17 inhibitors (subgroup)
- RR, 95% CI 1.07-1.59
- 1.30
Serious infections
- No increased risk of serious infections was shown
Safety
- No increased risk of serious infections was shown
Original publication
Risk of infections in psoriatic arthritis or axial spondyloarthritis patients treated with targeted therapies: A meta-analysis of randomized controlled trials. Joint Bone Spine. Published 30 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →